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THROMBOSIS AND HEMOSTASIS
Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet
activation-dependent fibrin formation at low shear flow
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A microscopic method was developed to
study the role of platelets in fibrin forma-
tion. Perfusion of adhered platelets with
plasma under coagulating conditions at a
low shear rate (2501) resulted in the
assembly of a star-like fibrin network at
the platelet surface. The focal fibrin forma-
tion on platelets was preceded by rises in
cytosolic Ca2, morphologic changes, and
phosphatidylserine exposure. Fibrin for-
mation was slightly affected by IIb3
blockage, but it was greatly delayed and
reduced by the following: inhibition of
thrombin or platelet activation; interfer-
ence in the binding of von Willebrand
factor (VWF) to glycoprotein Ib/V/IX
(GpIb-V-IX); plasma or blood from pa-
tients with type 1 von Willebrand disease;
and plasma from mice deficient in VWF or
the extracellular domain of GpIb. In this
process, the GpIb-binding A1 domain of
VWF was similarly effective as full-length
VWF. Prestimulation of platelets enhanced
the formation of fibrin, which was abro-
gated by blockage of phosphatidylserine.
Together, these results show that, in the
presence of thrombin and low shear flow,
VWF-induced activation of GpIb-V-IX trig-
gers platelet procoagulant activity and
anchorage of a star-like fibrin network.
This process can be relevant in hemosta-
sis and the manifestation of von Wille-
brand disease. (Blood. 2011;117(2):
651-660)
Introduction
Platelets have prominent and divergent roles in the stimulation of
blood coagulation. In vivo and in vitro evidence indicates that
platelet-associated tissue factor triggers the extrinsic coagulation
pathway.1,2 In the presence of collagen, platelets contribute to the
intrinsic, factor XII–dependent pathway of coagulation.3,4 Further-
more, platelets stimulated by combinations of potent platelet
agonists produce large amounts of thrombin because of exposure of
phosphatidylserine (PS). This negatively charged phospholipid
provides a surface on which the tenase and prothrombinase
complexes assemble to produce factor Xa and thrombin, respec-
tively.5,6 Such platelets have been termed procoagulant or coated
platelets; the latter designation refers to their property to assemble a
protein coat consisting of granule-derived proteins, coagulation
factors, fibrin(ogen), and von Willebrand factor (VWF).7,8 Under
static conditions, the procoagulant platelet response is suppressed
by IIb3 antagonists,9,10 suggesting that this integrin has a
regulating role in the coagulation process.
The glycoprotein Ib-V-IX (GpIb-V-IX) complex, expressed at
more than 20 000 copies per platelet, can act as a ligand for VWF
and various coagulation factors. Quantitative or qualitative abnor-
malities either in the GpIb-V-IX complex (in Bernard-Soulier
syndrome) or in VWF (in von Willebrand disease [VWD]) are
accompanied by impaired hemostasis and increased bleeding
risk.11,12 Although this points to a general role of GpIb-V-IX in
platelet function, the signaling consequences of VWF–GpIb-V-IX
interaction have mostly been studied under flow at high arterial
shear rates.11 However, there is limited evidence for a role of VWF
and GpIb in the coagulation process in the absence of high-shear
flow. It has been reported that VWF in the presence of fibrin
stimulates GpIb-dependent thrombin generation under semistatic
conditions.13,14 In coagulation, VWF can have a carrier function for
factor VIII (FVIII) and supply this factor to a growing throm-
bus.15,16 Other authors propose a coagulation-stimulating role of
GpIb by interaction with factor VIIa or thrombin17,18 or a function
of GpIb in fibrin binding to IIb3, VWF, or thrombin.19-21 Hence,
the GpIb-V-IX complex seems to be a central component in the
interaction of platelets with VWF, thrombin and the coagulation
end-product, fibrin. However, it is unclear whether the GpIb-V-IX
complex merely acts as an assembling component of these plasma
factors or also has an active role in establishing activation of
these factors.
In this paper, we describe a new role of platelets operating under
low-shear flow conditions: the focal formation of fibrin fibers. We
demonstrate that this process actively relies on VWF-GpIb-V-IX–
mediated platelet stimulation in the presence of thrombin traces,
and a subsequent local burst of thrombin generation. Furthermore,
we do not find a major contribution in this process of IIb3
activation or FVIII supply by VWF.
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Apyrase, bovine serum albumin (BSA), and prostaglandin E1 (PGE1) were
obtained from Sigma-Aldrich; corn trypsin inhibitor (CTI) from Haemato-
logic Technologies; and VWF-deficient plasma from Affinity Biologicals.
Ristocetin, recombinant human tissue factor (Innovin), and FVIII-deficient
plasma came from Dade Behring; SFLLRN and the fluorogenic thrombin
substrate, Z-GGR-AMC, from Bachem; and thrombin substrate S2238 from
Chromogenics. Fluo-4 and Fura-2 acetoxymethyl ester; Oregon Green
(OG) 488–labeled annexin A5; Alexa Fluor (AF)647-labeled annexin
A5 and OG488- and AF546-labeled fibrinogen were from Invitrogen.
Cathepsin G and H-Phe-Pro-Arg chloromethyl ketone (PPACK) were from
Calbiochem, and O-sialoglycoprotein endopeptidase from Cedarlane Labo-
ratories. Recombinant human VWF A1 domain was provided by Drs B. de
Laat and P. G. de Groot (University Medical Center, Utrecht, The
Netherlands).22
Monoclonal antibodies (mAbs) against the N-terminal1-289 globular
domain of GpIb were generated, as described before.23-25 The 2D2 mAb
blocks the thrombin binding site of GpIb; 6B4 interferes with the
shear-induced and ristocetin/botrocetin-induced binding of VWF to GpIb;
12G1 blocks only the shear-induced binding of VWF to GpIb; 2D4 is an
isotope-matched control antibody. Anti-VWF mAb 418, blocking the
interaction with FVIII, was provided by Dr P. Lenting (Inserm 770, Paris,
France).26 Rabbit anti–human VWF and control antibodies were from
Dako; fluorescein isothiocyanate (FITC) anti-CD62P mAb was from
Beckman Coulter; blocking anti–P-selectin mAb AK4 from BD PharMin-
gen. Chimeric mAb, abciximab, directed against IIb3 and v3, was from
Centocor; the nonpeptide IIb3 antagonist, tirofiban, from Merck; fibrino-
gen -chain dodecapeptide, HHLGGAKQAGDV, interfering with a differ-
ent fibrinogen-binding sequence on IIb than RGDS, was obtained from
Anaspec.
Healthy participants and patients
Blood was taken from healthy volunteers and 2 patients with type 1 VWD.
Subjects gave full informed consent, and had not taken medication
interfering with coagulation or platelet function for at least 2 weeks. Patient
plasmas contained 10%-12% of normal ristocetin cofactor activity, al-
though tissue factor–induced thrombin generation was in the normal range.
Animals
Animal experiments were approved by the Thomas Jefferson University
animal experimental committees. Transgenic IL4R/GpIb mice27 and
mice homozygous for VWF deficiency28 were generated as described, and
bred against a C57Bl/6 genetic background. In the IL4R/GpIb mice,
most of the extracellular domain of GpIb is replaced by the extracellular
domain of the human interleukin-4 receptor . Mice were provided by Drs
J. Ware (University of Arkansas) and D. Wagner (Harvard Medical School,
Boston, MA). Platelet surface glycoproteins were in the normal range.
Plasmas from VWF/ mice were devoid of VWF oligomers or multimers.
Blood collection and platelet preparation
Human blood was collected into 1/10 volume of 129mM trisodium citrate,
and used to prepare platelet-rich plasma (PRP) and washed platelets.4 Blood
collection was approved by the Maastricht University Medical Ethical
Committee. Where indicated, platelets in plasma were loaded with 8M of
Fluo-4 acetoxymethyl ester.4 Washed platelets were resuspended at
100  109/L in Hepes buffer pH 7.45 (10mM Hepes, 136mM NaCl, 2.7mM
KCl, 2mM MgCl2, 0.1% glucose, and 0.1% bovine serum albumin [BSA])
containing apyrase (0.1 U/mL). If needed, platelets were pretreated with
cathepsin G (400nM)29 or O-sialoglycoprotein endopeptidase (0.1 mg/
mL)30 for 1 hour at 37°C, and washed again. Platelet count was determined
with a thrombocounter (Coulter Electronics). Platelet-free pooled plasmas
were prepared by differential centrifugation of citrate-anticoagulated blood
from 6 to 10 healthy donors. Pooled plasmas were aliquoted and immedi-
ately snap-frozen at 80°C until use.
Blood from wild-type and knockout mice was drawn under anesthesia
and collected into 1/10 volume of 129mM trisodium citrate.31 Mouse
PRP and washed platelets were prepared as before.32 Purified platelets were
resuspended at 100  109/L into Tyrode-Hepes buffer pH 7.45 (5mM
Hepes, 136mM NaCl, 2.7mM KCl, 0.42mM NaH2PO4, 2mM MgCl2,
0.1% glucose, and 0.1% BSA) with 0.1 U/mL apyrase. Citrate-anticoagu-
lated platelet-free plasma from animals was obtained by differential
centrifugation33 and immediately snap-frozen. Where indicated, washed
mouse platelets were pretreated with O-sialoglycoprotein endopeptidase
(0.1 mg/mL) for 30 minutes at 37°C.30
Platelet analysis and activation in suspension
Expression of GpIb levels on platelets was determined by flow cytometry
using FITC-labeled anti–human GpIb mAb M1638 (Sanquin), or anti–
mouse GpIb M043 mAb (Emfret). Agonist-induced rises in [Ca2]i were
measured as described.4
Microscopic measurement of fibrin formation under flow
Degreased, uncoated glass coverslips were placed into a transparent
parallel-plate flow chamber (dimensions: 50 m deep and 3 mm wide),
mounted at the stage of an inverted fluorescence microscope (Diaphot
200; Nikon), and rinsed with Hepes buffer pH 7.45. Coverslips in a flow
chamber were incubated for 10-15 minutes under stasis with a suspension
of washed platelets (100  109/L). Remaining unbound platelets were
removed by 5 minutes of perfusion with Hepes buffer pH 7.45 containing
1% BSA to prevent further platelet spreading. Coating time was adjusted to
achieve adhesion of 22  4 platelets per microscopic field of 95  95 m.
Adhered platelets were superfused with citrate-anticoagulated plasma and
CaCl2-containing medium at a calculated total shear rate of 250 s1. For the
human system, 10 vol/vol of human plasma were coperfused with 1 vol/vol
of 100mM Hepes, 75mM CaCl2, and 37.5mM MgCl2 (pH 7.45). For the
mouse system, 3 vol/vol of mouse plasma were coperfused with 1 vol/vol
of 136mM Hepes, 20mM CaCl2 and 7mM MgCl2 (pH 7.45). At 60 seconds
after the start of fibrin formation (lag time recorded), coverslips were
stained with labeled annexin A5 (0.5 g/mL) and/or labeled fibrinogen
(100 g/mL). During flow, phase contrast and fluorescent images were
recorded using a 100/1.3 NA oil immersion objective and a sensitive
electron multiplier (EM) CCD camera system (Hamamatsu Sciences).
Images from mouse platelets were recorded as described.31 Agonists or
antagonists and fluorescent probes were added to the blood or plasma, as
indicated. To measure rises in [Ca2]i, platelets were loaded with Fluo-4
acetoxymethyl ester before adhesion.4
Confocal microscopy and image analysis
Dual color confocal images were recorded with a 60/1.4 NA oil
immersion objective and a BioRad/Zeiss laser scanning microscope system
capable of electronic zooming.34 Confocal overlays with differential
interference contrast images were produced with a Leica SP5 multiphoton
laser-scanning system. For quantification, bright-field and fluorescence
images were analyzed from more than 8 arbitrarily chosen microscopic
fields. Subtracted phase-contrast images were generated using Metamorph
software Version 7.5.0.0 (MDS Analytical Technologies), and analyzed for
changes in pixel intensity above background without any contrast
enhancement.
Thrombin generation in plasma
Thrombin generation was measured in pooled human plasma by determin-
ing cleavage of fluorogenic Z-GGR-AMC, as before.35 Coagulation was
triggered with tissue factor (1pM) or kaolin (1.5 g/mL) and CaCl2
(16.6mM, no phospholipids added unless indicated). Thrombin was also
measured in plasma samples (50 L) taken at the outlet of the flow
chamber, collected into stop buffer (50mM Tris, 175 mM NaCl and 10mM
ethylenediaminetetraacetic acid [EDTA], pH 7.9).
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Statistics
The significance of differences was determined with the nonparametric
Mann-Whitney U test and the paired sample t test (intervention effects),
using the statistical package for social sciences (SPSS Version 11.0).
Results
Platelets promote star-like fibrin fiber formation under flow
A microscopic flow chamber method was developed to investigate
the role of platelets in fibrin formation under flow conditions.
Washed human platelets adhering to glass coverslips were perfused
with plasma or blood that was recalcified to trigger coagulation.
Coverslips were then blocked with Hepes buffer containing
1% BSA to prevent contact activation by the glass surface.
Perfusion with normal pooled plasma at a low shear rate of 250 s1
(but not at high shear rates) caused the sudden formation of
star-like fibrin fibers on the majority of adhered platelets after a
10-minute lag time (Figure 1A). In control experiments with
blocked coverslips not containing platelets, fibrin remained absent
during more than 25 minutes, while tissue factor addition resulted
in parallel fibrin fibers formed in the direction of flow (Figure 1A).
With adhered platelets, inhibition of FVIIa (active-site inhibited
FVIIa) or FXIIa (corn trypsin inhibitor) resulted in a 2-fold delay in
star-like fibrin formation. This indicated that under these flow
conditions both the intrinsic and extrinsic pathways contributed to
overall coagulation process.
High-magnification microscopic images demonstrated a steadily
growth in length of the fibrin fibers produced on platelets (Figure
1B; supplemental Video, available on the Blood Web site; see the
Supplemental Materials link at the top of the online article). From
subtraction images, the increase in fiber length was calculated at
	 1 m/s (supplemental Figure 1A-B), while the onset of fibrin
formation was determined at 	 580 seconds (Figure 1C). Plasma
samples taken at the outlet of the flow chamber showed the
presence of substantial amounts of thrombin, but only if platelets
were present (Figure 1D). Under stasis, importantly, plasma
recalcification did not result in measurable thrombin generation,
unless tissue factor (lag time, 10 minutes) or kaolin (lag time,
19 minutes) was added (supplemental Figure 1C). Hence, in the
flow experiments, the adhered platelets strongly promote the
generation of thrombin and subsequent fibrin formation.
Activation of platelets is required for star-like fibrin formation
Bright-field and fluorescence microscopic images were recorded to
determine the activation state of adhered platelets during perfusion
with plasma. Before fibrin formation, most platelets displayed
pseudopods (type 1) or lamellipods (type 2) while retaining a thick
core. This indicated normal spreading over the surface. During
flow, most of the cells changed into translucent structures with
ruffled edges and a lost core (type 3), or into round, blebbing cells
(type 4; Figure 2A). The type 3 and 4 structures resemble the
description of cells with Sustained Ca2 Induced Platelet (SCIP)
morphology.8,36 Platelet activation was confirmed by staining with
OG488–annexin A5, showing PS exposure of most type 3/4 cells
(Figure 2B). Labeling of annexin A5 was detectable after 	 4 min-
utes of plasma perfusion, that is, before the appearance of fibrin
(Figure 2C). Adhering Fluo-4–loaded platelets showed potent rises
in cytosolic Ca2 starting after 	 3 minutes of perfusion (Figure
2D). Finally, after 12 minutes, 89% of the platelets showed exposed
PS, while 96% showed fibrin stars (Table 1). In the presence of
thrombin inhibitor PPACK, Ca2 responses as well as PS exposure
and fibrin formation were almost abolished.
Labeling with OG488-fibrinogen confirmed the star-like appear-
ance of the fibrin fibers produced on platelets (supplemental Figure
2A). Colabeling with AF546-VWF indicated 	 50% pixel-by-
pixel overlap with OG488-fibrin(ogen), which is in agreement with
the known ability of VWF to bind fibrin (supplemental Figure 2D).
Labeled OG488-factor Xa gradually accumulated at the platelet
Figure 1. Platelet-dependent fibrin formation under
flow. Coverslips with or without adhered platelets were
perfused with pooled plasma under recalcification at a
low shear rate of 250 s1. (A) Representative phase-
contrast images taken at 580-640 seconds after start (ie,
during the first minute of fibrin formation). Image record-
ing with a Nikon Diaphot 200 microscope as described in
“Methods.” Right panels show differential, subtracted
images (bars, 10 m). Note the parallel fibrin fibers in the
direction of flow on perfusion with tissue factor (1pM).
(B) High magnification images of star-like fibrin fibers on
platelets. (C) Quantification of fibrin fibers from sub-
tracted images. Increases in mean pixel intensity are
shown. (D) Thrombin activity in plasma samples collected
from the flow chamber outlet. Means  SE (n 
 3-4
experiments); ***P  .001 vs control.
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surface, indicating factor Xa-dependent prothrombinase activity
(supplemental Figure 2C). Although fibrin-forming platelets
exposed P-selectin (supplemental Figure 2B), the blocking anti–
P-selectin mAb AK4 (20 g/mL) did not affect the lag time to fibrin
formation (93%  7% of control) nor the appearance of the fibers.
To determine whether platelet activation is required for fibrin
formation, adhered cells were treated with PGE1, causing elevation
in Cyclic adenosine monophosphate (cAMP), before perfusion
with plasma. This treatment significantly increased the lag time
to start of fibrin formation from 9.3  0.5 minutes to
12.7  1.4 minutes (P  .05; n 
 4). Few of the PGE1-treated
platelets formed fibrin fibers and no longer had a star-like
appearance (Figure 3A). Treatment with PGE1 led to a marked
reduction in the increase of Ca2 and to diminished staining with
labeled annexin A5 and fibrinogen (Figure 3B-D).
A thrombin receptor role was studied by platelet pretreatment
with the protease cathepsin G, which cleaves PAR isoforms as well
as GpIb from the cell surface.37-39 Control experiments confirmed
Figure 2. Morphologic activation score of fibrin-forming platelets. (A), Different morphologies of adhered platelets superfused with normal plasma at low shear rate of
250 s1. Start of fibrin formation was at 580 seconds. Numbers in italic refer to platelets with different structures: 1, platelet with pseudopods and core; 2, platelet with
lamellipods and core; 3, translucent platelet without core, forming ruffled edges; 4, bleb-forming platelet with rounded structure (bars, 10 m). (B), Fluorescence images after
postlabeling with OG488–annexin A5. (C), Time-dependent increase in OG488–annexin A5 fluorescence during plasma perfusion (arbitrary fluorescence units per cell,
mean  SE, n 
 12). Arrow points to start of fibrin formation. (D), Representative [Ca2]i rises of single adhered platelets during plasma perfusion, expressed as pseudo-ratio
F/Fo values. Where indicated, PPACK (40M) or 6B4 mAb (20 g/mL) was present in plasma. Microscopic images and Ca2 traces recorded with a Nikon Diaphot
200 microscope as described in “Methods.”
Table 1. Effect of various treatments on platelet activation and fibrin formation under flow
Treatment
Fraction of adhered platelets
Types 3 and 4 PS-exposing Fibrin-forming
Initial (0 min)
Control 0.12  0.07 0.06  0.03 0
After perfusion (12 min)
Control 0.79  0.04 0.89  0.02 0.96  0.04
PPACK 0.14  0.04* 0.10  0.05* 0
Cathepsin G 0.10  0.03* 0.16  0.09* 0.02  0.01*
Annexin A5 0.08  0.01* N.d. 0.01  0.01*
Adhered platelets were superfused with recalcified plasma at 250 seconds1, as described in Figure 1. Plasma was incubated with PPACK (40M) or unlabeled annexin
A5 (20 g/mL), as indicated. Alternatively, platelets were pretreated with cathepsin G (400nM). After 0-12 minutes of perfusion, adhered platelets were classified as types 1-4
(pseudopods, lamellipods plus core, translucent without core, and bleb-forming, respectively) from phase-contrast images. Adhered platelets were counted as PS-exposing
(staining with OG488-annexin A5) and forming fibrin fibers. Values reported are means  SE (n 
 3-6 experiments).
N.d. indicates not determined.
*P  .01 compared with control.
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Figure 3. Effects of PGE1 on platelet activation and fibrin formation. Platelets were superfused with plasma at 250 s1 in the absence (control) or presence (0.5M) of
PGE1. Bright-field and contrast images (Nikon Diaphot 200 microscope, see “Methods”) were taken at 0-60 seconds after start of fibrin formation (bars, 10 m). (A) Reduced
fibrin on platelets after PGE1 treatment (average pixel intensities of subtracted images). (B) Lower [Ca2]i rises with PGE1 in Fluo-4–loaded platelets. (C) Lower
OG488–annexin A5 staining with PGE1. (D) Reduced OG488-fibrin(ogen) staining (integrated fluorescent intensities). Means  SE; n  3; *P  .05, ***P  .001 vs control.
Figure 4. Role of platelet GpIb-V-IX in fibrin formation under flow. Platelets were superfused with plasma at 250 s1 in the presence (10 g/mL) of isotype control mAb
2D4 or one of the following anti-GpIb mAbs: 2D2 (block of thrombin binding site), 12G1 (block of shear-induced VWF binding) or 6B4 (block of shear- and ristocetin-induced
VWF binding). (A) Representative microscopic images (Nikon Diaphot 200 microscope, see “Methods”) were taken at 0-60 seconds after start of fibrin formation: phase
contrast and OG488-fibrin(ogen) (bars, 10 micron). (B) Lag time to start of fibrin formation. (C) Quantification of fibrin formation from subtracted images (60 seconds).
(D) Staining with OG488-fibrin(ogen). (E) Fractions of platelets positive for OG488–annexin A5. Means  SE; n 
 3-4; ***P  .001 vs control mAb.
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that the cathepsin G treatment greatly reduced thrombin-induced
Ca2 mobilization and GpIb surface expression (supplemental
Figure 3A-B). The treated platelets adhered normally, but, on
perfusion with plasma, only 10%-16% developed a type 3/4
morphology and exposed PS, while no fibrin was formed (Table 1).
Perfusion of untreated platelets in the presence of 20 g/mL
annexin A5, which blocks procoagulant cell membranes,35 also
abolished fibrin formation (Table 1). On the other hand, platelet
treatment with the PAR-1 agonist SFLLRN was without effect (not
shown). Together, these data showed the need of prior platelet
activation and PS exposure for star-like fibrin formation.
Role of GpIb-V-IX but not IIb3 in platelet fibrin formation
A possible role of integrin IIb3 was then studied. Adhered
platelets were perfused with plasma containing one of the follow-
ing IIb3 blockers: the chimeric mAb abciximab (20 g/mL); the
nonpeptide inhibitor tirofiban (5 g/mL); or dodecapeptide derived
from the fibrinogen -chain (200M), which blocks a unique
epitope on the IIb chain. Surprisingly, these integrin blockers only
slightly affected the time to fibrin formation on platelets or fibrin
growth (supplemental Figure 4).
A contribution of the GpIb-V-IX complex was studied by using
a panel of mAbs (10 g/mL) against different epitopes of the
extracellular domain of GpIb. The 2D2 mAb directed against the
thrombin binding site on GpIb influenced neither the lag time nor
the extent of fibrin formation, in comparison to control mAb 2D4
(Figure 4A-B). On the other hand, the blocking mAbs 12G1 and
6B4, which are both directed against the VWF binding site on GpIb,
provoked marked prolongation of the lag time, accompanied by a major
reduction in the amount of fibrin formed during 1 minute (Figure
4C-D). Most platelets retained their type 2 morphology, and no
fibrin was formed during 25 minutes. The 6B4 mAb also markedly
prolonged and reduced the Ca2 responses (Figure 2D), while both
mAbs abrogated PS exposure (Figure 4E). These results suggest a
role of the VWF-binding domain of GpIb in platelet activation and
subsequent fibrin formation.
Role of VWF-GpIb interaction in platelet fibrin formation
We studied a possible role of VWF in the formation of fibrin by
knowing the partial colocalization of platelet-bound GpIb ligand
VWF with fibrin. First, normal plasma was incubated with
ristocetin to stimulate the interaction of VWF with platelet GpIb.
The ristocetin incubation significantly shortened the lag time to
fibrin formation, while the amount of fibrin formed was unchanged
(Figure 5A-B). Second, plasma was used from 2 patients with type
1 VWD (both with 10%-12% of normal ristocetin cofactor
activity). With either plasma, fibrin formation on adhered platelets
was significantly delayed and diminished in comparison to control
plasma (Figure 5). In addition, the fractions of PS-exposing
platelets were reduced from 76% to 19%  3% (control vs patient
plasmas). Ristocetin treatment of patient plasmas did not alter the
lag time or the extent of fibrin formation.
The importance of the GpIb-V-IX–VWF axis for fibrin forma-
tion was also studied in the mouse. Similar to the human system,
low-shear flow of recalcified wild-type mouse plasma resulted in
star-like formation of fibrin fibers on 80% of adhered platelets after
a 12-minutes lag time. In marked contrast, essentially no fibrin
formed up to 25 minutes, when using platelets and plasma from
mice lacking the extracellular domain of GpIb or from mice with
VWF deficiency (Figure 6A-B). To further confirm the importance
of GpIb, wild-type platelets were treated with O-sialoglycoprotein
endopeptidase, which cleaves off the 45 kD N-terminal region of
mouse GpIb.40 This treatment resulted in  95% loss of the
surface expression of GpIb (supplemental Figure 3C). On plasma
perfusion, only 3%  3% of adhered endopeptidase-treated plate-
lets bound annexin A5 (compared with 72% of untreated platelets),
while the lag time to fibrin formation was lengthened to more than
25 minutes. Together, these results demonstrated a key role of
VWF and GpIb in platelet activation and fibrin formation in the
mouse system as well.
In subsequent experiments, adhered human platelets were
prestimulated with ionomycin to provoke exposure of PS (Figure
7A-B). On perfusion, this greatly shortened the lag time to fibrin
formation from 9.3  0.5 minutes to 4.3  0.8 minutes (Figure
7C-D). In this case, VWD plasma was similarly effective as control
plasma. Notably, however, the anti-GpIb 6B4 mAb prolonged this
lag time again to 8.3  0.7 minutes, still pointing to a role of the
GpIb-V-IX complex in fibrin fiber assembly.
Because FVIII in plasma is bound to VWF,15 a possible role of
VWF was investigated as local supplier of FVIII to the platelets. As
expected, FVIII was required for coagulation, as perfusion with
FVIII-deficient plasma did not result in fibrin formation on
platelets. Reconstitution of this plasma with recombinant FVIII
(Kogenate; Bayer) restored the time to fibrin formation from more
than 20 minutes to 6.3  1.3 minutes. Control plasma was then
incubated with the anti-VWF mAb 418 (40 g/mL), which
displaces FVIII from VWF.26 This mAb did not increase, but
Figure 5. Role of plasma VWF in platelet fibrin formation under flow. Platelets
were superfused with pooled plasma from control subjects (control) or from 2 patients
with VWD at shear rate of 250 s1. Ristocetin (37.5 g/mL) was added as indicated.
Microscopic images were taken at start and after 60 seconds of fibrin formation.
(A) Lag time to start of fibrin formation. (B) Quantification of OG488-fibrin(ogen)
binding. Means  SE; n 
 3-4; *P  .05, ***P  .001 vs control plasma.
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insignificantly reduced the time to fibrin formation from 9.7  1.4 to
7.0  1.0 minutes (P 
 .18). As an alternative approach, the effect
of recombinant VWF A1 domain was tested, which represents the
GpIb–binding domain of VWF and does not interact with FVIII.22
Reconstitution of VWF-deficient plasma with FVIII (Kogenate,
1 U/mL) decreased the time to fibrin formation on platelets from
 25 minutes to 15.1  3.4 minutes (P  .05). Markedly, coaddi-
tion of A1 domain (5 g/mL) further accelerated the fibrin
formation to 7.5  1.8 minutes, that is, similar to full-size VWF.
Hence, the binding of VWF A1 domain to GpIb-V-IX appears to be
sufficient for triggering fibrin formation on platelets, while a role of
VWF-FVIII binding was not detectable.
Role of fibrin formation via GpIb-V-IX and VWF in
flowing whole blood
To study the fibrin formation on platelets under physiologically
relevant conditions, experiments were performed using recalcified
whole blood. High-shear perfusion of blood over adhered platelets
did not result in fibrin or thrombus formation. By stepwise
lowering of the flow rate, star-like fibrin fibers on platelets
appeared at a shear rate of 125 s1 (Figure 8A). The fibrin
formation was accompanied by deposition of platelets from the
blood and thrombus formation. During low-shear flow, fluores-
cence from AF647–annexin A5 and AF547-fibrinogen was re-
corded in real time by dual color confocal microscopy. A gradual
accumulation was observed of annexin A5 fluorescence (PS
exposure), which within 20 seconds was followed by the appear-
ance of AF547-fibrin fibers (Figure 8A-B). Both PS exposure and
fibrin formation were delayed and diminished with VWD blood or
with control blood containing the 12G1 anti-GpIb mAb. Further-
more, high-resolution images confirmed that also in whole blood
PS-exposing platelets served as focal points for star-like fibrin
formation (Figure 8C). In sum, these results point to a role of
GpIb-V-IX and VWF in fibrin formation on platelets also in whole
blood flowed at low shear rate.
Discussion
This article describes a new function of platelets operating under
low-shear flow conditions to propagate the formation of star-like
fibrin fibers at their surface. Mechanistically, this process relies on
platelet activation evoked by VWF binding to GpIb-V-IX in the
presence of traces of thrombin. The evidence comes from experi-
ments showing that the fibrin formation on platelets in the presence
of flow and coagulation is enhanced by ristocetin, antagonized by
antibodies blocking the shear-dependent interaction of GpIb with
full-size VWF or VWF A1 domain, impaired in plasma or blood
from VWD patients, greatly delayed in blood from mice deficient
in VWF or the extracellular domain of GpIb, and no more than
slightly affected by integrin IIb3 inhibition.
The time-dependent measurements show that during flow with
plasma, adhered platelets assume an activated state (elevated Ca2,
type 3/4 morphology, PS exposure, factor Xa binding) before the
start of fibrin formation. This activation is nearly abolished in the
presence of PPACK, thus pointing to role of in situ formed
thrombin as coagonist. In addition, platelet inhibition with PGE1
abrogates platelet Ca2 rises and PS exposure, again accompanied
by a delay and reduction in fibrin formation. This points to a
scenario where the immobilized platelets respond to small amounts
of thrombin in flowing plasma, which enforces VWF- and GpIb-
mediated signaling to result in full platelet activation. Via a local
enforcement loop, platelet-exposed PS activates coagulation factor
complexes, which then generate sufficiently high thrombin amounts
to ensure the focal fibrin formation. The importance of flow and
Figure 6. Roles of murine GpIb-V-IX and VWF on platelet-dependent fibrin formation under flow. Adhered platelets from wild-type (WT) mice, transgenic mice lacking the
extracellular domain of GpIb (IL4R/GpIb), or mice deficient in VWF were superfused with autologous plasma at a shear rate of 250 s1. (A) Representative bright-field
images (bars, 20 m) after 0-60 seconds of fibrin formation, as well as images of OG488-fibrin(ogen). Images were recorded as described.31 (B) Lag time to start of fibrin
formation. (C) Fractions of fibrin-forming platelets during 25 minutes perfusion. Means  SE; n 
 4-6 mice; ***P  .001 vs WT.
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GpIb in this process, in synergy with thrombin, is clearly demon-
strated by the delayed and reduced platelet Ca2 rises, PS exposure,
and fibrin formation with blocking anti-GpIb mAbs 6B4 and 12G1,
which specifically recognize an VWF-binding epitope on GpIb
that is exposed by shear or ristocetin/botrocetin-induced activa-
tion.23 Similarly, GpIb cleavage (by cathepsin G or O-sialoglyco-
protein endopeptidase), GpIb absence, or paucity in VWF (VWD
patients and deficient mice) greatly impairs platelet PS exposure
along with fibrin formation. A specific role of VWF as carrier for
FVIII in (thrombin and) fibrin formation is not detected. This
proposal is further supported by the finding that platelet preactiva-
tion with ionomycin, causing immediate PS exposure, enhances
fibrin formation. However, blockage of GpIb still delays this
process, indicating a role of GpIb independent of platelet activation.
The present recognition of VWF- and GpIb-mediated PS
exposure and fibrin formation sheds a new light on several earlier
findings. It is compatible with the known ability of GpIb-V-IX to
provide a binding site for coagulation factors, VWF and, via VWF,
for fibrin.17,24,41,42 While other authors have shown that platelets
can adhere to fibrin via GpIb,18,20,42 the present data indicate that
this binding also provides a means for attachment of growing fibrin
fibers at the platelet surface. Our data confirm a role of GpIb-V-IX
in thrombin generation,13,17 but they also show that at least under
flow this role is independent of preformed fibrin, IIb3 activation
or thrombin binding to GpIb. Furthermore, VWF appears to be
important not only for stimulating platelet procoagulant activity,
but also for focal fibrin formation.
The importance of VWF-induced platelet activation via GpIb
has extensively been documented at high-shear flow conditions,
provoking shear-dependent conformational changes in VWF and
GpIb.43,44 Interestingly, we find that, in the presence of low shear
rate (250 s1) and in situ formed thrombin, blocking of the
shear/ristocetin-induced binding of VWF to GpIb (6B4, 12G1
mAbs) effectively reduces platelet activation and fibrin formation.
On the other hand, blocking of the thrombin binding site on GpIb
(2D2 mAb) is not effective. This points to a previously unrecog-
nized VWF-induced GpIb-activating effect probably dependent on
the presence of thrombin that results in platelet procoagulant
activity and operates at low shear conditions. This might indicate
that, under coagulant conditions with (traces of) thrombin present,
a low shear rate can cause similar conformational changes,
facilitating VWF interaction with GpIb and platelet activation, as
was previously reported for high shear rates. The relevance of these
findings comes from animal studies demonstrating that deficiency
in GpIb or VWF affects not only arterial but also venous
thrombus formation.45,46 This indeed suggests a prothrombotic
function of both proteins also at low, venous shear flow conditions.
Plasma perfusion carried out in the presence of corn trypsin
inhibitor or inactivated factor VIIa show a twofold prolongation of
the time to fibrin formation. The contribution of factor XII relies on
the presence of adhered platelets because, under flow, no fibrin is
formed without platelets. An interesting explanation is that platelets
in some way trigger the contact activation system, eg by producing
polyphosphates, which have been demonstrated to activate factor
Figure 7. Rapid fibrin formation on ionomycin-stimulated platelets. Adhered platelets were prestimulated with ionomycin (10M) and CaCl2 (1mM), then perfused with
control plasma (Ctrl) or plasma from a patient with VWD in the presence or absence of 6B4 mAb (10 g/mL). (A) Representative phase contrast and OG–annexin
A5 fluorescence images (Nikon Diaphot 200 microscope, see “Methods”) after ionomycin stimulation (bars, 10 m). (B) Fractions of type 3 and 4 (procoagulant) platelets
before plasma perfusion. (C) Platelet-dependent fibrin formation after 240 seconds. (D) Lag time to fibrin formation after plasma perfusion. Means  SE; n 
 3-4.




 http://ashpublications.org/blood/article-pdf/117/2/651/1338517/zh800211000651.pdf by guest on 22 Septem
ber 2021
XII.47 The result may be enhanced thrombin generation, and
thereby fibrin generation. Further studies will resolve this issue.
The studies performed with mouse plasma and platelets provide
some insight into the GpIb activation mechanism, because adhered
platelets expressing the chimeric IL4R/GpIb, lacking the extra-
cellular domain of GpIb, are unable to support fibrin formation, in
spite of the fact that the intracellular domain of the glycoprotein
normally interacts with filamin-1 and 14-3-3.27 Hence, other
activation pathways play a role, probably involving protein ty-
rosine kinases.48 Given the present data, the severe bleeding
phenotype retained in these mice may be linked to defective
platelet activation and fibrin formation. Similarly, in humans, this
mechanism of platelet-dependent fibrin formation at low shear rate
can be relevant for normal hemostasis, and may contribute to the
bleeding risk seen in patients with deficiencies in VWF or
GpIb-V-IX complex.
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13. Béguin S, Kumar R, Keularts I, Seligsohn U,
Coller BS, Hemker HC. Fibrin-dependent platelet
procoagulant activity requires GpIb-V-IX recep-
tors and von Willebrand factor. Blood. 1999;93(2):
564-570.
14. Keuren JFW, Ulrichts H, Feijge MAH, et al. Inte-
grin alphaIIbbeta3 and shear-dependent action of
glycoprotein Ibalpha stimulate platelet-dependent
thrombin formation in stirred plasma. J Lab Clin
Med. 2003;141(5):350-358.
15. Weiss HJ, Sussman II, Hoyer LW. Stabilization of
factor VIII in plasma by the von Willebrand factor.
Studies on posttransfusion and dissociated factor
VIII and in patients with von Willebrand’s disease.
J Clin Invest. 1977;60(2):390-404.
16. Kawasaki T, Kaida T, Arnout J, Vermylen J,
Hoylaerts MF. A new animal model of thrombo-
philia confirms that high plasma factor VIII levels
are thrombogenic. Thromb Haemost. 1999;81(2):
306-311.
17. Weeterings C, De Groot PG, Adelmeijer J,
Lisman T. The glycoprotein Ib-V-IX complex con-
tributes to tissue factor-independent thrombin
generation by recombinant factor VIIa on the acti-
vated platelet surface. Blood. 2008;112(8):3227-
3233.
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